The overall goal of the Molecular Genetics of Human Tumors Program is to stimulate new research and to enhance existing multidisciplinary programs in molecular genetics as applied to human solid tumors. This is a highly collaborative program involving faculty in four departments (Medicine, Surgery, Radiation and Cellular Oncology and Pathology). It evolved naturally by collaborations between investigators with experience in molecular genetics of hematologic tumors and investigators with experience in biologic studies of solid tumors. Although the program is newly conceived, it has an excellent scientific foundation that will benefit from improved organization and defined leadership. The objectives of the Program are to strengthen existing research efforts in human solid tumors, to encourage the development of new research programs by providing technology and interactions and to promote the involvement of clinical scientists in basic research programs either by laboratory or clinical correlative studies. A major emphasis of this program is on the sharing of technology and of tissue resources. The program also provides a resource for the training of predoctoral and postdoctoral students supported by the Cancer Biology Training Grant, the Environmental Biology Training Grant, the Surgical Oncology Training Grant and for clinical fellowship training programs in Hematology-Oncology, Gastroenterology and Radiation and Cellular Oncology, as well as for individual fellowship awards from public and private agencies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-27
Application #
6397822
Study Section
Project Start
2000-08-01
Project End
2002-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
27
Fiscal Year
2000
Total Cost
$289,716
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Liu, Hongtao; Zha, Yuanyuan; Choudhury, Noura et al. (2018) WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol 7:1
Nageeb, Shaheen; Vu, Milkie; Malik, Sana et al. (2018) Adapting a religious health fatalism measure for use in Muslim populations. PLoS One 13:e0206898
Ferreira, Caroline M; Williams, Jesse W; Tong, Jiankun et al. (2018) Allergen Exposure in Lymphopenic Fas-Deficient Mice Results in Persistent Eosinophilia Due to Defects in Resolution of Inflammation. Front Immunol 9:2395
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24
Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650
Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914
Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231
Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188

Showing the most recent 10 out of 668 publications